BCD-263 not checked

Biocad

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
89 active
112 in total · 110 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles”In the company’s words, NCT06640530 on ClinicalTrials.gov
Tested for
Advanced Melanoma (2 trials), Melanoma (Skin)
Main trialPhase 3
“The aim of the study BCD-263-2/UNIVERSE is to demonstrate comparable efficacy and similar safety and immunogenicity profile of BCD-263 and Opdivo after repeated intravenous doses in subjects with advanced unresectable or metastatic melanoma of the skin.”In the company’s words, NCT06640530 on ClinicalTrials.gov
Other names
Nivolumab
Given with
Opdivo (Bristol Myers Squibb)Other companies’ drugs in its trials

Other drugs for Advanced Melanoma

All 195 drugs for Advanced Melanoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials112

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Dec 2025 Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Phase 1Active, not recruiting 31 Jan 2024 A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Phase 2Authorised not given METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer – Shaping Anti-Tumor Immunity by Oxaliplatin
Phase 2Authorised not given Immunotherapy in patients with early dMMR rectal cancer. A Danish DCCG phase II trial
Phase 2Authorised not given Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
Phase 2Authorised not given HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements
Phase 2Authorised not given WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE OR NEOADJUVANT TARGETED TREATMENT IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY
Phase 2Authorised not given A window-of-opportunity trial with high-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colorectal cancer: the ALFEO pilot study
Phase 2/3Authorised not given Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)
Phase 3Authorised not given CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Phase 3Authorised not given First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)
Phase 2Authorised not given NEoadjuvant Chemotherapy and Immunotherapy for a selected group of inoperable pleural Mesothelioma patients (NECIM): a feasibility study
Phase 2Authorised not given Immunological variables associated to ICI toxicity in cancer patients
Phase 3Ended not given INTEGRATE IIb A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Phase 3Authorised not given A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients with Uveal Melanoma Liver Metastases – the SCANDIUM III trial
Phase 2Authorised not given EORTC-1525-LCG: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)
Phase 2Authorised not given TRIFLUOX-DP: Safety of Trifluridine/tipiracil as replacement of fluoropyrimidines (5-fluorouracil and capecitabine) based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with dihydropyrimidine dehydrogenase deficiency: a phase II trial
Phase 2Authorised not given A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
Phase 2Authorised not given A phase Ib/II randomized double-blind placebo controlled trial evaluating the effect of nivolumab for patients with in-transit melanoma metastases treated with isolated limb perfusion
Phase 2Authorised not given Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX)
Phase 3Authorised not given Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratification (NivoMela)
Phase 1/2Ended not given A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladder sparing curative treatment for muscle invasive bladder cancer: the CRIMI study
Phase 2Ended not given OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS
Phase 2Ended not given CONGRATS : COMBINATION OF NIVOLUMAB PLUS RELATLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOFT-TISSUE SARCOMA: A PROOF-OF-CONCEPT RANDOMIZED PHASE II STUDY
Phase 3Authorised not given A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS
Phase 3Authorised not given A prospective randomized international multicenter study to compare Short versus Long Adjuvant immunotherapy after radical surgery of stage IIb-c, III and IV cutaneous malignant Melanoma (Grand SLAM)
Phase 1/2Authorised not given Combinatory ImmunoTherapy-2 (Com-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer
Phase 1/2Authorised not given Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer Cohorts – (INEC study) – A Phase I/II trial (CA209-9M9 study)
Phase 1/2Authorised not given A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (Indi-Blade)
Phase 2Authorised not given Phase II clinical trial of Neo-adjuvant chemo/immunotherapy followed by adjuvant treatment depending on the resection status for the treatment of NSCLC patients diagnosed with pancoast tumor. A multicenter exploratory study_DUMAS
Phase 2Ended not given A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers
Phase 2Ended not given Breaking the big Five Barriers of Brain Metastasis: A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain CA209-7WF / Break B5-BM-NSCLC
Phase 2Authorised not given LOGICAN : Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin ± nivolumab versus FOLFOX ± nivolumab in patients with HER2 negative locally advanced, recurrent or metastatic gastric, oesophageal or junctional adenocarcinoma
Phase 2Ended not given Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)
Phase 2Ended not given Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer
Phase 3Authorised not given A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN)
Phase 2Authorised not given Immune induction strategies to improve response to immune checkpoint blockade in triple negative breast cancer (TNBC) patients: the TONIC-2 trial
Phase 2Authorised not given Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial
Phase 1/2Ended not given Metro-PD1-1708: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors
Phase 3Authorised not given Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA
Phase 2/3Ended not given Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study
Phase 2Authorised not given Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin
Phase 3Authorised not given MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
Phase 3Authorised not given A phase III clinical trial of adjuvant chemotherapy vs chemo-immunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients_NADIM-ADJUVANT
Phase 2Ended not given A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemo-therapy alone for the treatment of locally advanced and potentially resectable non-small cell lung cancer (NSCLC) patients_NADIM II
Phase 2Ended not given Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC) patients with synchronous Brain metastases_NIVIPI-Brain
Phase 2/3Authorised not given TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC
Phase 2Ended not given Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor Treatment - The FRACTION Trial
Phase 3Ended not given RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype
Phase 1/2Authorised not given Intrathecal application of PD-1 antibody in metastatic solid tumors with leptomeningeal disease
Phase 2Ended not given Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer (SOGUG-VEXILLUM)
Phase 1/2Authorised not given CAPTIRALL _ Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence
Phase 1/2Authorised not given INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies (INFORM2-NivEnt)
Phase 3Ended not given IFCT-1701 DICIPLE A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Phase 3Authorised not given Strategic treatment Pause of first-line Immune Check point inhibitor + Inhibitor in good or only one adverse prognostic factor in intermediate risk metastatic renal cell carcinoma (mRCC) with an objective response: a randomized, non-inferiority phase III study - SPICI
Phase 1/2Ended not given Phase I-II trial of sunitinib and/or nivolumab plus chemotherapy in advanced soft tissue and bone sarcomas
Phase 1/2Ended not given An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refractory Acute Myeloid Leukemia and in Combination with 5-Azacytidine and Venetoclax for Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Negative for NPM1 and IDH 1/2 Mutations Who Are Ineligible for Intensive Chemotherapy (AARON)
Phase 2Authorised not given Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negative interim PET after 2 chemotherapy cycles (RAFTING-2019)
Phase 2Authorised not given Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1-line therapy.
Phase 2Authorised not given Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial)
Phase 2Authorised not given Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for recurrence or distant metastases (NESCIO-trial; M21NSC; CA209-6DJ)
Phase 1/2Authorised not given CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission tomography in patients with locally advanced or metastatic solid tumors
Phase 3Authorised not given Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial. PIPAC_VEROne
Phase 1/2Authorised not given (CHOPI) Phase 1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal Melanoma.
Phase 2Authorised not given Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing extensive curative surgery and radiotherapy: Matisse-2
Phase 2Authorised not given A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III rectAl cancer
Phase 2Ended not given Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial
Phase 2Authorised not given Immune-Related Rheumatological and neurological Adverse Events study (IRRAE study)
Phase 4Authorised not given Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-reported-outcome evaluation (CABOLD)
Phase 4Authorised not given Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
Phase 2Authorised not given Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2) - NIVO ALCL
Phase 2Authorised not given Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma: phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab and ipilimumab - ADJORL1
Phase 3Authorised not given Safe Stop Trial: observational study of the STOP & GO strategy of PD-1 blockade in advanced melanoma patients upon achieving a complete or partial response
Phase 3Authorised not given Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
Phase 2Ended not given A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA-4 blockade (PROMIT: PReconditioning of TumOr, Tumor Microenvironment and the Immune System to ImmunoTherapy)
Phase 1/2Authorised not given A randomized phase II clinical trial on intratumoral AS01B/ipilimumab plus intravenous nivolumab with or without autologous CD1c(BDCA-1)+ / CD141(BDCA-3)+ myeloid dendritic cells.
Phase 2Authorised not given Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)
Phase 4Authorised not given Evolution of the cardiac function during the follow-up of the anticancer immunotherapy inhibiting PD-1. IMMUNOCARD
Phase 2Authorised not given Phase II study evaluating the efficacy of Nivolumab in the treatment of patients with nasopharyngeal cancer who progressed during or after platinum-based chemotherapy
Phase 4Authorised not given CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY
Phase 1Authorised not given A phase IB clinical trial on neoadjuvant and intraoperative intracranial administration of triple immune checkpoint blockade plus myeloid dendritic cells in patients with recurrent high-grade glioma
Phase 2Authorised not given Analysis of the efficacy and safety of two combination treatment regimens of nivolumab and ipilimumab in patients with dMMR and / or MSI metastatic colorectal cancer: A GERCOR open-label, randomized, non-comparative, two-stage phase II trial (NIPISAFE)
Phase 1/2Ended not given LAPTOP: PHASE 1/2 STUDY IN BORDELINE RESECTABLE, LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER TO ASSESS SAFETY AND POTENTIAL EFFICACY OF DUAL CHECKPOINT INHIBITION IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL FOLLOWED BY IMMUNE-CHEMORADIATION.
Phase 2Authorised not given A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progressing after first-line chemo-immunotherapy (Combi-TED)
Phase 2Authorised not given A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases
Phase 4Authorised not given Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE)
Phase 2Authorised not given A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1
Phase 2Authorised not given Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer. (CA209-6E8, CNN-BC trial)
Phase 4Authorised not given Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: The CANIQOL multicentre study
Phase 2Ended not given A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
Phase 2Authorised not given Randomized phase 2 study of Simvastatin in patients with ARID1A mutated advanced gastrooesophageal carcinoma treated with Nivolumab and Oxaliplatin-based chemotherapy as first-line treatment (The ARES trial).
Phase 3Authorised not given SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma
Phase 2Authorised not given IMMUNOPEC: Combination of neo-adjuvant Checkpoint Inhibition and Dendritic Cell Therapy (MesoPher) with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with Peritoneal Mesothelioma
Phase 4Authorised not given ETCABio - Evaluation of Skin Tests in Biotherapy Allergies
Phase 2Authorised not given A Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer
Phase 2Authorised not given Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple-negative breast cancer (TNBC) patients: TONIC-trial
Phase 4Authorised not given (CO2MO) A prospective, multicenter clinical performance study to evaluate IOpener®-melanoma test for predicting response to combination or mono immunotherapy in stage III or IV cutaneous melanoma patients.
Phase 2Authorised not given NOCANO: Nivolumab as neoadjuvant immunotherapy for patients with Oral CANcer and identification of response-predictive biomarkers in tumour draining lymph NOdes
Phase 2Authorised not given Ipilimumab and nivolumab plus temozolomide and capecitabine for patients with chemo-refractory pMMR, MGMT silenced metastatic colorectal cancer: The MAYA2 trial
Phase 2Authorised not given NEOREM/NEO-1 - NEOREM : Neo-adjuvant Adaptive Master Trial for Localized Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / NEO-1 : Neo-adjuvant intratumoral Anti-CTLA4 + Anti-PD1 treatment in patients with localized melanoma
Phase 3Authorised not given IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator-initiated multicentre randomised phase 3 trial (M24IMS)
Phase 2Authorised not given IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease
Phase 2Authorised not given Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).
Phase 4Authorised not given BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology
Phase 3Authorised not given Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.
Phase 2Authorised not given Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors
Phase 1/2Authorised not given COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients
Phase 3Authorised not given Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)
Phase 4Authorised not given Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma
Phase 2/3Authorised not given DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”
Phase 2Authorised not given Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high
Phase 2Not authorised not given The role of serum KIM-1 and MAdCAM-1 dynamics in early prediction of the efficacy of de-escalated systemic treatment in advanced renal cell carcinoma (STELA study).
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BCD-263

Following is part of Solo: you see every change to BCD-263 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in